Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Sunday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.6 %

Shares of NYSE BTX opened at $1.78 on Friday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock has a 50 day moving average of $2.11 and a 200-day moving average of $1.79. The company has a market capitalization of $104.71 million, a P/E ratio of -0.78 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.